JP2019048895A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019048895A5 JP2019048895A5 JP2018246722A JP2018246722A JP2019048895A5 JP 2019048895 A5 JP2019048895 A5 JP 2019048895A5 JP 2018246722 A JP2018246722 A JP 2018246722A JP 2018246722 A JP2018246722 A JP 2018246722A JP 2019048895 A5 JP2019048895 A5 JP 2019048895A5
- Authority
- JP
- Japan
- Prior art keywords
- citrullinated
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 208000035475 disorder Diseases 0.000 claims 7
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 108091006007 citrullinated proteins Proteins 0.000 claims 4
- 108010033040 Histones Proteins 0.000 claims 3
- 239000000090 biomarker Substances 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 102000008946 Fibrinogen Human genes 0.000 claims 2
- 108010049003 Fibrinogen Proteins 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940012952 fibrinogen Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000001179 synovial fluid Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102000018803 Calgranulin A Human genes 0.000 claims 1
- 108010052500 Calgranulin A Proteins 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 claims 1
- 108010073385 Fibrin Proteins 0.000 claims 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims 1
- 108700010013 HMGB1 Proteins 0.000 claims 1
- 101150021904 HMGB1 gene Proteins 0.000 claims 1
- 102100037907 High mobility group protein B1 Human genes 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 1
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 102000007000 Tenascin Human genes 0.000 claims 1
- 108010008125 Tenascin Proteins 0.000 claims 1
- 102000013127 Vimentin Human genes 0.000 claims 1
- 108010065472 Vimentin Proteins 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229950003499 fibrin Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000005048 vimentin Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361894042P | 2013-10-22 | 2013-10-22 | |
| US61/894,042 | 2013-10-22 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Division JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177986A Division JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019048895A JP2019048895A (ja) | 2019-03-28 |
| JP2019048895A5 true JP2019048895A5 (enExample) | 2019-09-12 |
Family
ID=51866128
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Pending JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2018246722A Withdrawn JP2019048895A (ja) | 2013-10-22 | 2018-12-28 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
| JP2020177986A Pending JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525584A Pending JP2016539925A (ja) | 2013-10-22 | 2014-10-22 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020177986A Pending JP2021006592A (ja) | 2013-10-22 | 2020-10-23 | Ｔｌｒ４リガンドまたは他のバイオマーカーのレベルが上昇した患者における障害の診断および処置を行うための方法および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9688769B2 (enExample) |
| EP (1) | EP3060250A1 (enExample) |
| JP (3) | JP2016539925A (enExample) |
| CN (1) | CN105899231A (enExample) |
| AU (2) | AU2014338991B2 (enExample) |
| CA (1) | CA2928317A1 (enExample) |
| WO (1) | WO2015059168A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6419064B2 (ja) * | 2012-03-29 | 2018-11-07 | ノビミューン エスアー | 抗ｔｌｒ４抗体およびその使用 |
| AU2014338991B2 (en) | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
| EP3332256A1 (en) * | 2015-08-06 | 2018-06-13 | NovImmune SA | Methods and compositions for identifying patient populations for diagnosis and treatment of tlr4-dependent disorders |
| JP6872024B2 (ja) * | 2016-10-04 | 2021-05-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 合成分類指標の同定のためのシステムおよび方法 |
| JP7108638B2 (ja) * | 2017-02-07 | 2022-07-28 | ライフストーン・アーエス | 無菌性弛みによるインプラント関連のインプラント再置換リスクの診断のためのバイオマーカー |
| WO2020225549A1 (en) * | 2019-05-06 | 2020-11-12 | The Francis Crick Institute Limited | Method for preventing inflammation |
| CA3174429A1 (en) * | 2020-04-20 | 2021-10-28 | Edesa Biotech Research Inc. | Compositions and methods for treatment of acute respiratory distress syndrome |
| CN113358872B (zh) * | 2021-06-03 | 2022-10-21 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于评估肿瘤免疫治疗疗效的标志物组及系统 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7674884B2 (en) * | 2003-12-10 | 2010-03-09 | Novimmune S.A. | Neutralizing antibodies and methods of use thereof |
| US7312320B2 (en) | 2003-12-10 | 2007-12-25 | Novimmune Sa | Neutralizing antibodies and methods of use thereof |
| ES2382039T3 (es) * | 2003-12-10 | 2012-06-04 | Novimmune Sa | Anticuerpos anti-TLR4/MD-2 neutralizantes y métodos de uso de los mismos |
| EP1789067B8 (en) | 2004-08-12 | 2012-08-15 | Helsinn Healthcare S.A. | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system |
| ES2348792T3 (es) * | 2004-12-10 | 2010-12-14 | Novimmune Sa | TERAPIAS COMBINADAS DIRIGIDAS A MÚLTIPLES RECEPTORES TIPO TOLL Y USO DE LAS MISMAS. |
| AU2006284096B2 (en) | 2005-08-25 | 2012-03-29 | Avro Life Sciences, Inc. | Polymer conjugates of K-252a and derivatives thereof |
| SI1919979T1 (sl) * | 2005-08-25 | 2014-02-28 | Creabilis Therapeutics S.P.A. | Polimerni konjugati K-252A in njihovi derivati |
| US20070148704A1 (en) * | 2005-10-06 | 2007-06-28 | Ursula Klause | Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis |
| US7712333B2 (en) | 2006-03-29 | 2010-05-11 | Asahi Glass Company, Limited | Method for smoothing a surface of a glass substrate for a reflective mask blank used in EUV lithography |
| WO2009101479A2 (en) * | 2007-05-14 | 2009-08-20 | Novimmune Sa | Fc receptor-binding polypeptides with modified effector functions |
| US8202650B2 (en) | 2007-07-24 | 2012-06-19 | Panasonic Corporation | Negative electrode material for nickel-metal hydride battery and treatment method thereof, and nickel-metal hydride battery |
| WO2009138494A2 (en) | 2008-05-15 | 2009-11-19 | Ablynx N.V. | Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors |
| US9140701B2 (en) * | 2009-08-18 | 2015-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Fibrinogen immune complexes to diagnose and guide therapy in rheumatoid arthritis |
| HRP20251174T1 (hr) * | 2010-11-05 | 2025-11-21 | Novartis Ag | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista |
| ES2721378T3 (es) * | 2011-01-10 | 2019-07-31 | Novimmune Sa | Anticuerpos anti-TLR4 y métodos de uso de los mismos |
| WO2013116590A1 (en) * | 2012-02-01 | 2013-08-08 | George Miller | Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors |
| US20160159922A1 (en) | 2013-07-24 | 2016-06-09 | Vilara Ab | Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis |
| AU2014338991B2 (en) | 2013-10-22 | 2020-06-11 | Novimmune S.A. | Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers |
-
2014
- 2014-10-22 AU AU2014338991A patent/AU2014338991B2/en not_active Ceased
- 2014-10-22 WO PCT/EP2014/072606 patent/WO2015059168A1/en not_active Ceased
- 2014-10-22 CA CA2928317A patent/CA2928317A1/en not_active Abandoned
- 2014-10-22 JP JP2016525584A patent/JP2016539925A/ja active Pending
- 2014-10-22 CN CN201480070143.8A patent/CN105899231A/zh active Pending
- 2014-10-22 US US14/520,904 patent/US9688769B2/en active Active
- 2014-10-22 EP EP14793805.4A patent/EP3060250A1/en not_active Withdrawn
-
2017
- 2017-06-26 US US15/632,882 patent/US10556960B2/en active Active
-
2018
- 2018-12-28 JP JP2018246722A patent/JP2019048895A/ja not_active Withdrawn
-
2020
- 2020-09-11 AU AU2020230333A patent/AU2020230333A1/en not_active Abandoned
- 2020-10-23 JP JP2020177986A patent/JP2021006592A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019048895A5 (enExample) | ||
| JP2020522261A5 (enExample) | ||
| US20200339703A1 (en) | Complex-specific antibodies and antibody fragments and its use | |
| Aletaha et al. | Therapeutic implications of autoantibodies in rheumatoid arthritis | |
| ES2989669T3 (es) | Anticuerpos monoclonales inmunoestimuladores contra interleucina 2 humana | |
| JP2016539925A5 (enExample) | ||
| US10590188B2 (en) | Antibody | |
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| JP2012012402A5 (enExample) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| Sekine et al. | Enrichment of anti-glomerular antigen antibody-producing cells in the kidneys of MRL/MpJ-Faslpr mice | |
| JP2017523984A5 (enExample) | ||
| JP2018535922A (ja) | 抗Ｎ−メチル−Ｄ−アスパラギン酸（ＮＭＤＡ）受容体抗体の結合領域に結合する抗体または抗体フラグメントまたは非Ｉｇ足場 | |
| JP7331168B2 (ja) | 多発性骨髄腫におけるｍタンパク質反応の臨床評価 | |
| JP2018507254A5 (enExample) | ||
| US20230236178A1 (en) | SPR-based dual-binding assay for the functional analysis of multispecific molecules | |
| CN112703204B (zh) | 针对可溶性bcma的抗体 | |
| Takeshita et al. | Antigen-driven autoantibody production in lungs of interstitial lung disease with autoimmune disease | |
| CN117069848B (zh) | 抗人cd146兔单克隆抗体及其应用 | |
| RU2016106708A (ru) | Лекарственное средство, содержащее антитело к фосфолипазе d4 | |
| CN116554323A (zh) | 人源化抗il21抗体的开发和应用 | |
| JP2022124478A (ja) | 成人スティル病の検査方法及び検査キット | |
| Sadeghian-Rizi et al. | Production of novel camelid anti-CXCL10 specific polyclonal antibodies and evaluation of their bioreactivity | |
| JP2020515286A5 (enExample) | ||
| CN115335402B (zh) | 特异性抗原结合分子,其制备方法及医药用途 |